Atopic Dermatitis (AD) Clinical Trial
Official title:
A Phase 3b Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy and Safety of Upadacitinib in Adolescent and Adult Subjects With Moderate to Severe Atopic Dermatitis in Brazil
Atopic Dermatitis (AD) is a chronic inflammatory skin disease that is characterized by intense itching, oozing and crusting, redness, skin erosion and dry skin. This study will evaluate how well upadacitinib compared to placebo (no medicine) works to treat participants with moderate to severe AD in Brazil. The study will assess change in disease signs and symptoms. Upadacitinib is an investigational drug being developed for the treatment of Atopic Dermatitis (AD). This study is "double-blinded", which means that neither the trial participants nor the study doctors will know who will be given which study drug. Study doctors put the participants into 1 of 4 groups called treatment arms. Each group receives a different treatment. Participants with a diagnosis of AD will be enrolled. Around 150 participants will be enrolled in the study in approximately 20 sites in Brazil. Participants will receive the following for up to 52 weeks: Participants will receive oral upadacitinib tablets once daily for up to week 52. Participants may also receive oral placebo tablets once daily up to week 16 followed by oral upadacitinib tablets once daily up to week 52. Arm 1: Upadacitinib Dose A up to week 52. Arm 2: Upadacitinib Dose B up to week 52. Arm 3: Placebo up to week 16 followed by upadacitinib Dose A up to week 52. Arm 4: Placebo up to week 16 followed by upadacitinib Dose B up to week 52. There may be higher burden for participants in this trial compared to their standard of care. Participants will attend monthly visits during the course of the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, and checking for side effects.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03151148 -
Targeted Microbiome Transplant in Atopic Dermatitis
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT05456529 -
Study of Ruxolitinib Cream in Adolescents With Atopic Dermatitis
|
Phase 3 | |
| Completed |
NCT04056130 -
A Study of Single and Multiple Ascending Doses of KBL697 in Healthy Subjects
|
Phase 1 | |
| Recruiting |
NCT04173442 -
Post-authorization Safety Study in North America to Monitor Pregnancy and Infant Outcomes Following Administration of Dupilumab During Planned or Unexpected Pregnancy
|
||
| Completed |
NCT05372653 -
A Long-term Trial of OPA-15406 in Infants With Atopic Dermatitis
|
Phase 3 | |
| Completed |
NCT03168113 -
Atopic Dermatitis (AD) and Food Allergy
|
N/A | |
| Terminated |
NCT03389893 -
Effect of Dupilumab (Anti-IL4Rα) on the Host-Microbe Interface in Atopic Dermatitis
|
Phase 4 | |
| Recruiting |
NCT04541810 -
A Study of Oral Upadacitinib (RINVOQ) Tablets to Assess Adverse Events and Change in Disease Symptoms in Korean Participants With Moderate to Severe Active Rheumatoid Arthritis, Atopic Dermatitis, Ankylosing Spondylitis or Psoriatic Arthritis
|
||
| Completed |
NCT02357940 -
Tolerance Evaluation of a Nighttime Moisturizing Balm on Babies and Adults With Eczema
|
N/A | |
| Recruiting |
NCT05667623 -
To Demonstrate the Superiority of IMP (1% OPA-15406 Ointment) to the Vehicle in Adult Patients With AD
|
Phase 3 | |
| Recruiting |
NCT05650320 -
To Demonstrate the Superiority of IMP (0.3% and 1% OPA-15406 Ointment) Versus the Vehicle in Pediatric Patients With AD
|
Phase 3 | |
| Completed |
NCT01979016 -
Study to Determine the Safety and Effectiveness of Dupilumab for Treatment of Atopic Dermatitis (AD)
|
Phase 2 | |
| Active, not recruiting |
NCT05959083 -
Real World Study of Oral Upadacitinib Tablets to Assess Adverse Events and Change in Disease Activity in Adolescent and Adult Chinese Participants With Atopic Dermatitis
|
||
| No longer available |
NCT04159597 -
Expanded Access to Upadacitinib
|